Skip to main content
. 2018 Apr 27;9(32):22509–22522. doi: 10.18632/oncotarget.25147

Figure 4. ERβ alters the chemosensitivity of breast cancer cells.

Figure 4

Survival of breast cancer cells was analyzed using MTS assay following treatment with the indicated drugs for 72 hours. (A) Survival of control (Lenti) and ERβ-expressing MCF-7 cells after treatment with the indicated concentrations of cisplatin. (B) Survival of control (Lenti) and ERβ-expressing MCF-7 cells after treatment with 10 nM DPN or 10 nM estradiol (E2) in the presence of 20 μM cisplatin (Cis). (C) Survival of control (Lenti) and ERβ-expressing MCF-7 cells after treatment with 1 μM 4-OHT alone or in combination with 20 μM cisplatin. (D) Survival of tamoxifen-sensitive (MCF-7) and -resistant (MCF-7-RR) breast cancer cells following treatment with 1 μM 4-OHT with or without 20 μM cisplatin. (E) mRNA levels of ERβ in MCF-7 and MCF-7-RR cells. Values were normalized to MCF-7 cells. (F) Survival of control (Lenti) and ERβ-expressing MCF-7-RR cells following treatment with increasing concentrations of 4-OHT in the absence and presence of 20 μM cisplatin. Values represent the mean ± S.D. of three different experiments.